{"id":40301,"date":"2017-09-12T09:35:45","date_gmt":"2017-09-12T13:35:45","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=40301"},"modified":"2017-09-12T09:35:46","modified_gmt":"2017-09-12T13:35:46","slug":"argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301","title":{"rendered":"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy"},"content":{"rendered":"<p>The stock of <strong>Argos Therapeutics Inc (NASDAQ:ARGS) <\/strong>closed at $0.20 losing 3.85% in yesterday\u2019s trading session. This provider today made a report outlining that for the first time a patient in the ongoing Phase 2 HIV eradication trial\u00a0was dosed with AGS-004 dendritic cell therapy. It was developed utilizing RNA antigens from the patient\u2019s latent viral reservoir in the University of North Carolina (UNC), and the product is expected to inspire hope to a large number of patients globally.<\/p>\n<p>To the best understanding of the business giant, this also shows up the first instance that a HIV patient in a clinical trial conducted in the United States will be utilizing the RNA antigens from the patient\u2019s latent viral reservoir.<\/p>\n<p>The latent viral reservoir\u00a0is made up of a wide range of infected immune cells. The fact that the HIV virus is dormant ends up hiding it from the attacks launched by the immune system.\u00a0Argos is currently spearheading an investigator-initiated clinical trial combining vorinostat, the latency-reversing agent with AGS-004.The Professor of Medicine at the University of North Carolina, David Margolis has been one of the major players in this particular trial.<\/p>\n<p>This trial is specifically cut out to put to test the hypothesis that boosting antiviral immunity with the active immunotherapy- AGS-004 in helping effectively eradicate the virus in this case scenario. The trial operates around the concept of sparking the large number of T cells in setting up the fight against the HIV-infected cells. Experts insist that the latency reversing drug will bear remarkable capabilities when it comes to exposing the virus in the latently infected cells associated with the human immune system.<\/p>\n<p>Chief Scientific Officer of Argos, Charles Nicolette <a href=\"https:\/\/globenewswire.com\/news-release\/2017\/09\/06\/1108300\/0\/en\/Argos-Announces-First-Dosing-of-HIV-Patient-with-AGS-004-Derived-from-the-Latent-Viral-Reservoir.html\" target=\"_blank\" rel=\"noopener\">opined<\/a>, \u201cWe believe that the new manufacturing process may allow AGS-004 to generate immune responses that are much better matched to the viral variants that will emerge during latency reversal with vorinostat treatment and, therefore, maximize the opportunity for viral clearance.\u201d<\/p>\n<p>He added that the strategy in a major way undermined the need for eligible patients to have archived infectious plasma prior to the initiation of anti-retroviral\u00a0medication.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The stock of Argos Therapeutics Inc (NASDAQ:ARGS) closed at $0.20 losing 3.85% in yesterday\u2019s trading session. This provider today made a report outlining that for [&hellip;]<\/p>\n","protected":false},"author":15,"featured_media":40308,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[12858,12857,12859],"stock_ticker":[],"class_list":["post-40301","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-argos-therapeutics-inc","tag-argos-therapeutics-inc-nasdaqargs","tag-nasdaqargs","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"The stock of Argos Therapeutics Inc (NASDAQ:ARGS) closed at $0.20 losing 3.85% in yesterday\u2019s trading session. This provider today made a report outlining that for [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-12T13:35:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-09-12T13:35:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"318\" \/>\n\t<meta property=\"og:image:height\" content=\"159\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Benjamin Roussey\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Benjamin Roussey\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301\"},\"author\":{\"name\":\"Benjamin Roussey\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\"},\"headline\":\"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy\",\"datePublished\":\"2017-09-12T13:35:45+00:00\",\"dateModified\":\"2017-09-12T13:35:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301\"},\"wordCount\":366,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg\",\"keywords\":[\"Argos Therapeutics Inc\",\"Argos Therapeutics Inc (NASDAQ:ARGS)\",\"NASDAQ:ARGS\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301\",\"name\":\"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg\",\"datePublished\":\"2017-09-12T13:35:45+00:00\",\"dateModified\":\"2017-09-12T13:35:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg\",\"width\":318,\"height\":159},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d\",\"name\":\"Benjamin Roussey\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g\",\"caption\":\"Benjamin Roussey\"},\"description\":\"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301","og_locale":"en_US","og_type":"article","og_title":"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy - Wall Street PR","og_description":"The stock of Argos Therapeutics Inc (NASDAQ:ARGS) closed at $0.20 losing 3.85% in yesterday\u2019s trading session. This provider today made a report outlining that for [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2017-09-12T13:35:45+00:00","article_modified_time":"2017-09-12T13:35:46+00:00","og_image":[{"width":318,"height":159,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg","type":"image\/jpeg"}],"author":"Benjamin Roussey","twitter_misc":{"Written by":"Benjamin Roussey","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301"},"author":{"name":"Benjamin Roussey","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d"},"headline":"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy","datePublished":"2017-09-12T13:35:45+00:00","dateModified":"2017-09-12T13:35:46+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301"},"wordCount":366,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg","keywords":["Argos Therapeutics Inc","Argos Therapeutics Inc (NASDAQ:ARGS)","NASDAQ:ARGS"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301","url":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301","name":"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg","datePublished":"2017-09-12T13:35:45+00:00","dateModified":"2017-09-12T13:35:46+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2017\/09\/40307-images__3_.jpeg","width":318,"height":159},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/argos-therapeutics-inc-nasdaqargs-pronounces-the-initial-dosing-of-hiv-patient-with-new-therapy-40301#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Argos Therapeutics Inc (NASDAQ:ARGS) Pronounces The Initial Dosing Of HIV Patient With New Therapy"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e82d48e74e653b113f0f9186826f808d","name":"Benjamin Roussey","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e051c9045b5c74768cca8f069d353d6ff45d41d241616ca1151ef20f3f86ff14?s=96&d=mm&r=g","caption":"Benjamin Roussey"},"description":"Benjamin Roussey is from Sacramento, California. He has two master\u2019s degrees and served four years in the U.S. Navy. His bachelor\u2019s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master\u2019s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http:\/\/www.facebook.com\/ben.rouss","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/benjamin-roussey"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40301","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=40301"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/40301\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/40308"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=40301"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=40301"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=40301"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=40301"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}